Wave Life Sciences Announced Results From Its Phase 1B/2A SELECT-HD Trial Of WVE-003 For Huntington's Disease, Demonstrating Mutant Huntingtin Lowering Of 46%, With Preservation Of Wild-type Huntingtin
Portfolio Pulse from Benzinga Newsdesk
Wave Life Sciences announced positive results from its Phase 1B/2A SELECT-HD trial of WVE-003 for Huntington's Disease, showing a 46% reduction in mutant huntingtin protein with preservation of wild-type huntingtin. The company plans to engage regulators for potential accelerated approval and submit an opt-in package to partner Takeda. The data validate Wave's RNA medicines platform and pipeline.
June 25, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wave Life Sciences announced positive results from its Phase 1B/2A SELECT-HD trial of WVE-003 for Huntington's Disease, showing a 46% reduction in mutant huntingtin protein with preservation of wild-type huntingtin. The company plans to engage regulators for potential accelerated approval and submit an opt-in package to partner Takeda.
The positive trial results and potential for accelerated approval are likely to boost investor confidence in Wave Life Sciences. The validation of their RNA medicines platform and upcoming milestones further support a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100